Abivax (ENXTPA: ABVX): Investor Relations Program
Abivax is a phase 3 ready clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases, and cancer. Their lead product, ABX464, will be advancing with a global pivotal phase 3 clinical study program in ulcerative colitis (UC). Abivax engaged with LifeSci in November, 2015.
LifeSci has worked extensively with Abivax since 2015 to optimize and improve company positioning to actively increase visibility amongst investors and strategics internationally. With iterative updates to company materials, LifeSci strives to provide in depth updates and reviews of all internal and external content.
LIFESCI’s ACTIVITIES
- Strengthened Abivax’s position globally as a leader in the Chronic Inflammatory Disease space
- Continuous corporate communications support including updates to all outreach materials, press releases, presentations, etc.
- Abivax annually attended LifeSci’s Corporate Access Event since 2016
- Target and maintain activity with prospective and current shareholders across Europe, Israel and the U.S.
RESULTS
This process ultimately led to two oversubscribed cross-over financings resulting in an uptick in the stock. Abivax was originally trading at EUR 7.63 on September 1st before their first cross-over financing of EUR 49.2 million and is now trading at EUR 16.2 after their recent deal in February of EUR 130 million, more than 2x the original trading price.
CLIENT TESTIMONIAL
“We have had the pleasure of working very closely with the LifeSci Advisors team since 2015. LifeSci’s expertise of the global investor community has made them our trusted partner through the series of strategic decisions we’ve made to structure Abivax as a renowned company in the chronic inflammatory diseases space. From frequent KOL events, non-deal roadshow investor meetings, and ongoing investor communications support (including through the global pandemic), to hosting us over the last 7 years at their Corporate Access Event in January in San Francisco, their execution has always been thoughtful and led to ongoing discussions and interest from relevant stakeholders. We have experienced a positive difference in our relationships within the financial community and believe that the connections cultivated through LifeSci alongside their strategic IR advice have ultimately led to three successful oversubscribed financings. On behalf of the Abivax team, we look forward to continuing to work together.”